tradingkey.logo

Biote Corp

BTMD
View Detailed Chart

3.390USD

-0.060-1.74%
Close 09/16, 16:00ETQuotes delayed by 15 min
107.44MMarket Cap
3.43P/E TTM

Biote Corp

3.390

-0.060-1.74%
Intraday
1m
30m
1h
D
W
M
D

Today

-1.74%

5 Days

-1.74%

1 Month

+16.10%

6 Months

-9.84%

Year to Date

-45.15%

1 Year

-42.15%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-15

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
67 / 167
Overall Ranking
178 / 4724
Industry
Professional & Commercial Services

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 6 analysts
Buy
Current Rating
5.403
Target Price
+60.34%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 19.54% year-on-year.
Undervalued
The company’s latest PE is 3.61, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 25.49M shares, decreasing 13.59% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 1.42M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.51.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

biote Corp. operates a practice-building business within the hormone optimization space. The Company provides the necessary components to enable Biote-certified practitioners to establish, build and implement a program designed to optimize hormone levels using personalized solutions for their patient populations. The Biote Method is a comprehensive, end-to-end practice building platform that provides Biote-certified practitioners with the components specifically developed for practitioners in the hormone optimization space: Biote Method education, training and certification, practice management software, inventory management software, and information regarding available hormone replacement therapy (HRT) products, as well as digital and point-of-care marketing support. It also sells a complementary Biote-branded line of dietary supplements. The Biote Method’s proprietary clinical decision support (CDS) software assists physicians in establishing individualized dosing for patients.
Ticker SymbolBTMD
CompanyBiote Corp
CEOMr. Bret Christensen
Websitehttps://haymakeracquisition.com/
KeyAI